Oncotarget

Reviews:

Association between MMP2-1306 C/T polymorphism and prostate cancer susceptibility: a meta-analysis based on 3906 subjects

Kaiping Zhang, Xianguo Chen, Jun Zhou, Cheng Yang, Meng Zhang, Min Chao, Li Zhang and Chaozhao Liang _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:45020-45029. https://doi.org/10.18632/oncotarget.16972

Metrics: PDF 1494 views  |   HTML 1875 views  |   ?  


Abstract

Kaiping Zhang1, Xianguo Chen2, Jun Zhou2, Cheng Yang2, Meng Zhang2, Min Chao1, Li Zhang2 and Chaozhao Liang2

1 Department of Urology, Anhui Provincial Children’s Hospital, Hefei, Anhui, China

2 Department of Urology, The First Affiliated Hospital of Anhui Medical University and Institute of Urology, AHMU, Hefei, Anhui, China

Correspondence to:

Chaozhao Liang, email:

Li Zhang, email:

Min Chao, email:

Keywords: MMP2, polymorphism, prostate cancer, susceptibility, Gleason grading

Received: September 14, 2016 Accepted: March 14, 2017 Published: April 08, 2017

Abstract

Numerous investigations have addressed the correlation between MMP2-1306C/T polymorphism and prostate cancer (PCa) susceptibility. However, these conclusions were controversial. Thus, we conducted this current meta-analysis based on six studies from PubMed, Embase, Cochrane Library, China Biology Medicine disc (CBM), China National Knowledge Infrastructure (CNKI) up to October 21st, 2016. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to evaluate the strength of the correlations. Additionally, different subgroup analyses and publication bias tests were performed. Eventually, six previous investigations consisted of 1920 cases and 1986 controls were identified and involved in this meta-analysis. Consequently, our evidence indicates a certain association between MMP2-1306C/T polymorphism and PCa risk among overall population (T vs C: OR = 1.12, 95% CI = 1.00-1.24, P = 0.040; TT+CT vs CC: OR = 1.16, 95% CI = 1.02-1.32, P = 0.026; respectively), as well as the subgroups of Asian population (T vs C: OR=1.48, 95% CI=1.13-1.94, P=0.004; TT+CT vs CC: OR = 1.66, 95% CI = 1.21-2.28, P = 0.002; respectively) and PCR-RFLP genotyped method (T vs C: OR = 1.58, 95% CI = 1.19-2.10, P = 0.001; TT+CT vs CC: OR = 1.71, 95% CI = 1.23-2.38, P = 0.001; respectively). However, no association was detected in MMP2-1306C/T polymorphism with Gleason grading or pathological stage of PCa. Our study indicates MMP2-1306 C/T polymorphism might increase PCa risk, particularly for Asian population. However, future studies comprising large cohort size from multicenter are required to confirm our conclusions.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16972